In recent studies, the potential of anti-VE-PTP antibodies, and a VE-PTP inhibitor, have been evaluated for use in vascular diseases and as therapeutic agents against breast cancer metastases, macular edema, neovascularization in the eye, and stroke [39,40,41,42,43]. Here, PTPRB is linked to macular retinal edema.